|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Dr. Neal S. Walker D.O.||Co-Founder, CEO & Director||965,59k||N/D||1970|
|Mr. Frank Ruffo||Co-Founder, CFO , Sec. & Treasurer||590,85k||N/D||1966|
|Dr. Joseph Monahan||Chief Scientific Officer||515,3k||N/D||N/D|
|Dr. Douglas J. Manion Frcp(C), M.D.||Pres & COO||N/D||N/D||1961|
|Mr. Matthew Rothman J.D.||VP of Legal & Compliance||N/D||N/D||N/D|
|Dr. Jon Jacobsen Ph.D.||Sr. VP of Chemistry||N/D||N/D||N/D|
|Dr. Paul S. Changelian Ph.D.||Sr. VP of Biology||N/D||N/D||N/D|
|Mr. James Loerop||Chief Bus. Officer||N/D||N/D||1965|
|Dr. Ian Anderson Ph.D.||Exec. VP of Translational R&D||N/D||N/D||N/D|
|Dr. Gail Cawkwell M.D., Ph.D.||Chief Medical Officer||N/D||N/D||1962|
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
L'ISS Governance QualityScore di Aclaris Therapeutics, Inc. al 1 settembre 2022 è 9. I criteri di valutazione fondamentali sono revisione: 8; Consiglio di Amministrazione: 8; diritti degli azionisti: 8; retribuzione: 10.